- Home
- URGN vs DGICB Comparison
URGN vs DGICB Comparison
Compare URGN & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- DGICB
- Stock Information
- Founded
- URGN 2004
- DGICB 1986
- Country
- URGN United States
- DGICB United States
- Employees
- URGN N/A
- DGICB N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- DGICB Property-Casualty Insurers
- Sector
- URGN Health Care
- DGICB Finance
- Exchange
- URGN Nasdaq
- DGICB Nasdaq
- Market Cap
- URGN 547.1M
- DGICB 504.0M
- IPO Year
- URGN 2017
- DGICB N/A
- Fundamental
- Price
- URGN $11.33
- DGICB $15.06
- Analyst Decision
- URGN Strong Buy
- DGICB
- Analyst Count
- URGN 5
- DGICB 0
- Target Price
- URGN $44.50
- DGICB N/A
- AVG Volume (30 Days)
- URGN 351.4K
- DGICB 928.0
- Earning Date
- URGN 11-06-2024
- DGICB 10-24-2024
- Dividend Yield
- URGN N/A
- DGICB 4.12%
- EPS Growth
- URGN N/A
- DGICB 148.60
- EPS
- URGN N/A
- DGICB 0.74
- Revenue
- URGN $89,363,000.00
- DGICB $979,119,004.00
- Revenue This Year
- URGN $13.39
- DGICB N/A
- Revenue Next Year
- URGN $45.06
- DGICB $5.78
- P/E Ratio
- URGN N/A
- DGICB $21.91
- Revenue Growth
- URGN 15.64
- DGICB 7.44
- 52 Week Low
- URGN $10.60
- DGICB $10.75
- 52 Week High
- URGN $20.70
- DGICB $16.81
- Technical
- Relative Strength Index (RSI)
- URGN 37.97
- DGICB 59.65
- Support Level
- URGN $11.10
- DGICB $14.26
- Resistance Level
- URGN $13.13
- DGICB $15.90
- Average True Range (ATR)
- URGN 0.53
- DGICB 0.53
- MACD
- URGN -0.10
- DGICB -0.02
- Stochastic Oscillator
- URGN 12.15
- DGICB 31.38
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.